Abiopharma

🔍 POLAN MARY LAKE PH D (Director)

Company: QuidelOrtho Corp (QDEL)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 15,532 shares of Restricted Stock Units (Equity Grant) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,532.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 5,547 shares of Restricted Stock Units (Converted) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,547.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 1,664 shares of Restricted Stock Units (Premium) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,664.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
• F2: The restricted stock units will vest on June 25, 2027.
• F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
• F4: 1,386 shares vested on June 25, 2026, 1,387 shares will vest on September 25, 2026, 1,387 shares will vest on December 25, 2026, and 1,387 shares will vest on March 25, 2027.